MA
CARM

MYDA Advisors’s Carisma Therapeutics CARM Stock Holding History

MYDA Advisors’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,500
Closed -$108K – 71
2018
Q3 		$108K Sell
2,500
-2,500
-50% -$97.4K 0.06% 123
2018
Q2 		$195K Buy
+5,000
New +$220K 0.09% 121

Other funds holding CARM

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
TG
TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CHP
Castle Hook Partners New York $23.4B AUM 158.96% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MYDA Advisors's CARM Position: Q4 2018 in Review

MYDA Advisors sold out of Carisma Therapeutics (CARM) in Q4 2018, closing a stake of 2,500 shares — an estimated $108K sold.

MYDA Advisors first reported a position in CARM in Q2 2018 and held it in 2 quarters. The position peaked at $195K in Q2 2018. 48 funds tracked by Wall St. Rank hold CARM as of Q4 2018.

  • MYDA Advisors reported no remaining Carisma Therapeutics position as of Q4 2018 after selling out during the quarter.
  • MYDA Advisors sold 2,500 Carisma Therapeutics shares in Q4 2018, an estimated $108K.
  • MYDA Advisors first reported a position in Carisma Therapeutics in Q2 2018 and held it in 2 quarters.
  • MYDA Advisors's Carisma Therapeutics position peaked at $195K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2018.

Based on MYDA Advisors's 13F filing for Q4 2018, filed 12 Feb 2019.